8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):January 14, 2025

Anteris Technologies Global Corp.

(Exact name of registrant as specified in itscharter)

Registrant’s telephone number, including

area code: +61 7 3152 3200

Not Applicable

(Former name or former address, if changed sincelast report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

On January 14, 2025 (January 15, 2025 in Australia), Anteris Technologies Global Corp. (the “Company”) lodged an announcement with the Australian Securities Exchange regarding the partial exercise of the over-allotment option in connection with the Company’s initial public offering (the “IPO”) and the end of the stabilisation period in connection with the IPO. A copy of the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Current Report on Form 8-K.

(d) Exhibits.

The following exhibit is filed with this Current Report on Form 8-K:

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit 99.1

ASX ANNOUNCEMENT

15 January 2025

Partial Exerciseof Over-Allotment Option and End of Stabilisation Period

Partial Exerciseof the over-allotment option

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) (Anteris or the Company) advises that, in connection with its initial public offering in the U.S. which closed on 16 December 2024 (U.S. time), TD Cowen, Barclays and Cantor (the Underwriters’ Representatives) have partially exercised the over-allotment option granted by the Company in respect of 78,481 shares of common stock of the Company (Common Stock) at the purchase price of US$6.00 per share, less underwriting discounts and commissions of $0.42 per share. The portion of the over-allotment option that was not exercised by the Underwriters’ Representatives lapsed on 11 January 2025 (U.S. time). Closing and settlement of the exercised portion of the over-allotment option occurred on 14 January 2025 (U.S. time).

End of StabilisationPeriod

The Company refers to the ‘no-action letter’ issued by the Australian Securities and Investments Commission in connection with the Company’s initial public offering in the U.S. (No Action Letter).

In connection with the market stabilisation arrangements regarding the Company’s Common Stock, the Company confirms that TD Cowen (StabilisationManager) ceased its market stabilisation activities on 12 January 2025, with the stabilisation period in connection the Company’s initial public offering in the U.S. therefore ceasing on 12 January 2025.

In accordance with the requirements of the No Action Letter, the Company advises that the market stabilisation and related activities undertaken by or on behalf of the Stabilisation Manager during the stabilisation period were as follows:

ENDS

860<br>Blue Gentian Road,<br><br> <br>Suite 340<br><br> <br>Eagan, MN, 55121<br><br> <br>United States<br><br> <br>T: +1 651 493 0606<br><br> <br>info.us@anteristech.com	Anteris<br> Technologies Global Corp.<br><br> <br><br><br> <br>BRISBANE	MINNEAPOLIS	GENEVA	MALAGA<br><br> <br>anteristech.com	Toowong<br> Tower, Level 3, Suite 302<br><br> <br>9 Sherwood Road<br><br> <br>Toowong, QLD<br> 4066<br><br> <br>Australia<br><br> <br>T: +61 1300 550<br> 310<br><br> <br>info.au@anteristech.com

About AnterisTechnologies Global Corp. (NASDAQ: AVR, ASX: AVR)

Anteris^®^Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR^®^Transcatheter Heart Valve (THV), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR^®^ THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.

DurAVR^®^THV is made using a single piece of molded ADAPT^®^ tissue, Anteris’ patented anti-calcification tissue technology. ADAPT^®^ tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The DurAVR^®^THV System is comprised of the DurAVR^®^ valve, the ADAPT^®^ tissue, and the balloon-expandable ComASUR^®^Delivery System.

Authorisationand Additional information

This announcement was authorised by the Board of Directors.

| 2 |

| --- |